Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
Fabrizio Martora, Massimiliano Scalvenzi, Teresa Battista, Luigi Fornaro, Luca Potestio, Angelo Ruggiero, Matteo Megna Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyCorrespondence: Fabrizio Martora, Section of Dermatology - Depart...
Main Authors: | Martora F, Scalvenzi M, Battista T, Fornaro L, Potestio L, Ruggiero A, Megna M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-09-01
|
Series: | Clinical, Cosmetic and Investigational Dermatology |
Subjects: | |
Online Access: | https://www.dovepress.com/guselkumab-risankizumab-and-tildrakizumab-in-the-management-of-hidrade-peer-reviewed-fulltext-article-CCID |
Similar Items
-
Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study
by: Matteo Megna, et al.
Published: (2022-08-01) -
Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023-12-01) -
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
by: Ruggiero A, et al.
Published: (2022-08-01) -
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report
by: Martora F, et al.
Published: (2024-02-01) -
Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease
by: Hannah S. Berman, et al.
Published: (2021-02-01)